Results 131 to 140 of about 1,338,765 (261)

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Laboratory Questionnaire; The Laboratory [PDF]

Journal of Chemical Education, 1925
openaire   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

Notes from the Field: Initial Public Health Response to a Measles Outbreak in a Close-Knit West Texas Community - January-February 2025. [PDF]

MMWR Morb Mortal Wkly Rep
Crisp CA, Milton S, Lutz CS, Northcott K, McClaran K, Hernandez C, Almas S, Holbrooks Z, Wells K, Sajewski E, Texas 2025 Measles Outbreak Response Team, CDC Epi-Aid Measles Response Team, Morrison A, Schroeder C, Nolen M, Gonzales J, Martinez D, Rai S, Shetty V, Shuford JA.   +19 more
europepmc   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Long-term monitoring of GMOs in EU food and feed: a multi-national survey to optimize enforcement strategies. [PDF]

GM Crops Food
Broothaerts W, de Andrade E, Hochegger R, Marchesi U, Weidner C.   +4 more
europepmc   +1 more source

LABORATORY

American Journal of Public Health and the Nations Health, 1928
C C, Young, M, Oglesby, H J, Knapp
openaire   +3 more sources

Laboratory Medicine

BioMed Research International, 2013
Hur, Mina, John, Andrew St., La Gioia, Antonio   +2 more
openaire   +2 more sources

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Navigating risk in biological quality testing: A guide for emerging laboratories. [PDF]

Indian J Med Res
Shrivastava R, Goel S, Trivedi N, Mishra N, Tewari S.   +4 more
europepmc   +1 more source